



67




or its pharmaceutically acceptable salt
wherein R¹ is H-phosphonate and R⁷ is H; and
R⁴ is NH₂.

16. A method for the treatment of a hepatitis C infection,
comprising:
providing to a human in need thereof an antivirally effective
amount of a compound of the structure:



or its pharmaceutically acceptable salt
wherein R¹ and R⁷ are both H; and
R⁴ is OH.


17. A method for the treatment of a hepatitis C infection,
comprising:
providing to a human in need thereof an antivirally effective
amount of a compound of the structure:



or its pharmaceutically acceptable salt
wherein R¹ is monophosphate and R⁷ is H; and
R⁴ is OH.


18. A method for the treatment of a hepatitis C infection,
comprising:
providing to a human in need thereof an antivirally effective
amount of a compound of the structure:

68




or its pharmaceutically acceptable salt
wherein R¹ is diphosphate and R⁷ is H; and
R⁴ is OH.

19. A method for the treatment of a hepatitis C infection,
comprising:
providing to a human in need thereof an antivirally effective
amount of a compound or its pharmaceutically
acceptable salt of the structure:



or its pharmaceutically acceptable salt
wherein R¹ is triphosphate and R⁷ is H; and
R⁴ is OH.

20. A method for the treatment of a hepatitis C infection,
comprising:
providing to a human in need thereof an antivirally effective
amount of a compound of the structure:



or its pharmaceutically acceptable salt
wherein R¹ is H-phosphonate and R⁷ is H; and
R⁴ is OH.

21. A method as recited in any one of the preceding claims,
wherein the antivirally effective amount of the compound is
administered in combination or alternation with at least one
treatment selected from the group consisting of an antiviral
treatment, an antibacterial treatment, an anticancer treatment,
and interferon.

* * * * *